PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 23 | 1 | 35-39
Article title

Kierunki w etiopatognezie pierwotnego zespołu Sjögrena

Content
Title variants
EN
Trends in etiopathogenesis of primary Sjögren’s syndrome
Languages of publication
PL EN
Abstracts
PL
Pierwotny zespół Sjögrena (PZS) należy do grupy chorób autoimmunologicznych. W swoim poważnym przebiegu wiąże się ze zwiększoną śmiertelnością poprzez zajęcie narządów wewnętrznych oraz rozwój chłoniaków B komórkowych. Dla PZS charakterystyczne jest tworzenie się nacieków limfocytarnych powodujących dysfunkcję gruczołów wydzielania wewnętrznego. Podobnie jak w wielu innych chorobach autoimmunologicznych nie są znane czynniki zapoczątkowujące proces chorobowy. U chorych na PZS stwierdza się typowe nacieki limfocytarne w gruczołach ślinowych. Pomimo, że nacieki te są dobrze scharakteryzowane, nie znamy dotychczas patogenezy ich powstawania. W pracy przedstawiono podsumowanie potencjalnych grup cytokin zaangażowanych w etiopatogenezę PZS.
EN
Primary Sjögren syndrome (pSS) is a systemic autoimmune disease and can be a serious disease with excess mortality due to severe organ-specific involvements and the development of B-cell lymphoma. PSS is characterized by lymphocytic infiltration of exocrine glands, resulting in glandular dysfunction. Similarly to many other autoimmune diseases, the inciting factors that precipitate pSS are poorly understood. Patients with pSS have specific lymphocytic infiltration of salivary glands. While this infiltration is well characterized, the pathologic events that precede and cause this inflammatory cell recruitment are unknown. This review summarizes the potential cytokine families involved in the etiopathogenesis of primary pSS.
Keywords
Discipline
Publisher
Year
Volume
23
Issue
1
Pages
35-39
Physical description
Contributors
  • Klinika Reumatologii i Chorób Wewnętrznych. Uniwersytecki Szpital Kliniczny we Wrocławiu
author
  • Klinika Reumatologii i Chorób Wewnętrznych. Uniwersytecki Szpital Kliniczny we Wrocławiu
References
  • 1. Moutsopoulos HM. Sjogren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994; 72: 162-5.
  • 2. Tzioufas AG, Kapsogeorgou EK, Manoussakis MN, Moutsopoulos HM. Pathogenetic aspects of primary Sjögren’s Syndrome. Diagnosis and therapeutics. (in) Sjogren’s syndrome. Ramos Casals M, Ston JH, Moutsopoulos HM (eds). Springer 2012: 33-55.
  • 3. Quartuccio L, Baldini C, Priori R, et al. Cryoglobulinemia in Sjögren Syndrome: a disease subset that links higher systemic disease activity, autoimmunity, and local b cell proliferation in mucosa-associated lymphoid tissue. J Rheumatol 2017; 44: 1179-83.
  • 4. Brito-Zerón P, Kostov B, Fraile G, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol 2017; 10: 90.
  • 5. Brito-Zeron P, Baldini C, Bootsama H, et al. Sjögren syndrome. Nature reviews. Disease Primers 2016; 2: 16047.
  • 6. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumathol 2013; 9: 544-56.
  • 7. Alunno A, Bistoni O, Bartoloni O, et al. IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren’s syndrome. Ann Rheum Dis 2013; 72: 286-92.
  • 8. Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM. Pathogenesis of Sjogren’s syndrome: what we know and what we should learn. J Autoimmun 2012; 39: 4-8.
  • 9. Kramer JM. Early events in Sjogren’s syndrome pathogenesis: The importance of innate immunity in disease initiation. Cytokine 2014; 67: 92-101.
  • 10. Fox R, Stern N. Sjogren’s syndrome: mechanism of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol 2002; 116(suppl): 3-13.
  • 11. Mavragani CP, Fragoulis GE, Moutsopoulos HM. Endocrine alterations in Primary Sjogren’s syndrome: an overview. J Autoimmun 2012; 39: 354-8.
  • 12. Retamozo S, Flores-Chavez A, Consuegra-Fernández M, et al. Cytokines as therapeutic targets in primary Sjögren syndrome. Pharmacol Ther 2017; doi: 10.1016/j.pharmthera.2017.10.019 [Epub ahead of print].
  • 13. Hansen A, Lipsky PE, Dorner T. B cells in Sjogren’s syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 2007; 9: 218.
  • 14. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infi ltrates in Sjogren’s syndrome. J Autoimmun 2010; 34: 400-7.
  • 15. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, et al. Foxp3+ T-regulatory cells in Sjogren’s syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 2008; 173: 1389-96.
  • 16. Skopouli FN, Fox PC, Galanopoulou V, et al i wsp. T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjogren’s syndrome. J Rheumatol 1991; 18: 210-4.
  • 17. Ohyama Y, Nakamura S, Matsuzaki G, et al. T-cell receptor V alpha and V beta gene use by infiltrating T cells in labial glands of patients with Sjogren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79: 730-7.
  • 18. Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum 2002; 46: 2160-71.
  • 19. Salomonsson S, Rozell BL, Heimburger M, et al. Minor salivary gland immunohistology in the diagnosis of primary Sjogren’s syndrome. J Oral Pathol Med 2009; 38: 282-8.
  • 20. Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun 2012; 39: 15-26.
  • 21. Świerkocka K, Łącki JK. Chłoniaki w zespole Sjögrena. Reumatol 2008; 46: 16-20.
  • 22. Turner MD. Salivary gland disease in Sjögren's syndrome: sialoadenitis to lymphoma. Oral Maxillofac Surg Clin North Am 2014; 26: 75-81.
  • 23. Gottenberg JE, Lavie F, Abbed K, et al. CD4 CD 25 high regulatory T cells are not impaired in patients with primary Sjögren’s syndrome. J Autoimmunol 2005; 24: 235-42.
  • 24. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren’s syndrome. Scand J Immunol 2005; 62: 421-8.
  • 25. Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013; 52: 276-81.
  • 26. Polihronis M, Tapinos NI, Theocharis SE, et al. Modes of epithelial cell death and repair in Sjögren’s syndrome (SS). Clin Exp Immunol 1998; 114: 485-90.
  • 27. Tapinos NI, Polihronis M, Moutsopoulos HM. Lymphoma development in Sjögren’s Syndrome. Arthritis Rheum 1999; 42: 1466-72.
  • 28. Delli K, Vissink A, Spijkervet FK. Salivary gland biopsy for Sjögren's syndrome. Oral Maxillofac Surg Clin North Am 2014; 26: 23-33.
  • 29. Sebastian A, Wiland P. Pierwotny zespół Sjögrena. (w) Reumatologia 2011/2012 - nowe trendy. Wiland P (red.). Termedia 2012: 177-88.
  • 30. Manoussakis MN, Boiu S, Korkolopoulou P, et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren’s syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007; 56: 3977-88.
  • 31. Skopouli FN, Dafni U, Ioannidis JP, et al. Clinical evolution, and morbidity and mortality of primary Sjogren’s syndrome. Semin Arthritis Rheum 2000; 29: 296-304.
  • 32. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum 2002; 46: 741-7.
  • 33. Gottenberg JE. Primary Sjögren's syndrome: pathophysiological, clinical and therapeutic advances. Joint Bone Spine 2009; 76: 591-4.
  • 34. Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008; 19: 263-76.
  • 35. Mackay F, Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006; 18: 284-9.
  • 36. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome. Oral Dis 2009; 15: 519-26.
  • 37. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome: potential therapeutic targets. Ann Rheum Dis 2010; 69: 945-8.
  • 38. Sindhava VJ, Tuna H, Gachuki BW, et al. Bone Marrow Dendritic Cell-Mediated Regulation of TLR and B Cell Receptor Signaling in B Cells. J Immunol 2012; 189: 3355-67.
  • 39. Coca A, Sanz I. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 2012; 24: 451-6.
  • 40. Mackay F, Sierro F, Grey ST, et al. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005; 8: 243-65.
  • 41. Novak AJ, Bram RJ, Kay NE, et al. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100: 2973-9.
  • 42. Batten M, Fletcher C, Ng LG, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004; 172: 812-22.
  • 43. Stohl W. Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin Ther Targets 2004; 8: 177-89.
  • 44. Mariette X. How does BAFF activate B cells in patients with autoimmune diseases? Arthritis Res Ther 2012; 14: 106.
  • 45. Mariette X, Gottenberg JE. Pathogenesis of Sjögren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010; 22: 471-7.
  • 46. Lavie F, Miceli-Richard C, Quillard J, et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjö- gren's syndrome. J Pathol 2004; 202: 496-502.
  • 47. Kang EH, Lee YJ, Hyon JY, et al. Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios. Clin Exp Rheumatol 2011; 29: 970-6.
  • 48. Nordmark G, Alm GV, Rönnblom L. Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2006; 2: 262-9.
  • 49. Trantafyllopoulou A, Tapinos N, Moutsopoulopus HM. Evidence for Coxackie-virus infection in primary Sjögren’s syndrome. Arthritis Rheum 2004; 50: 2897-902.
  • 50. Mariette X, Gozlan J, Clerc D, et al. Detection of Epstein–Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjögren’s syndrome. Am J Med 1991; 90: 286-94.
  • 51. Perrot S, Calvez V, Escande JP, Dupin N, et al. Prevalences of herpesviruses DNA sequences in salivary gland biopsies from primary and secondary Sjögren’s syndrome using degenerated consensus PCR primers. J Clin Virol 2003; 28: 165-8.
  • 52. Pflugfelder SC, Crouse C, Pereira I, et al. Amplification of Epstein– Barr virus genomic sequences in blood cells, lacrimal glands, and tears from primary Sjögren’s syndrome patients. Ophthalmology 1990; 97: 976-84.
  • 53. Wagner HJ, Hornef M, Teichert HM, Kirchner H. Sex difference in the serostatus of adults to the Epstein-Barr virus. Immunobiology 1994; 190: 424-9.
  • 54. Pasoto SG, Natalino R, Chakkour HP, et al. EBV reactivation serological profile in primary Sjögren’s syndrome: an underlying trigger of active articular involvement? Rheumatol Int 2013; 33: 1149-57.
  • 55. Kuwana Y, Takei M, Yajima M, et al. Epstein-Barr virus induces erosive arthritis in humanized mice. PLOS 2011; 6: e26630.
  • 56. Zandman-Goddard G, Berkun Y, Barzilai O, et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci 2009; 1173: 658-63.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-9876c4cc-9749-4bed-9db6-001b279314ba
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.